Core Viewpoint - Rocket Pharmaceuticals faced a significant decline in stock value after the FDA placed a clinical hold on its Phase 2 trial for RP-A501, leading to a 62% drop in share price on May 27, 2025, following the announcement of a patient's serious adverse event and subsequent death [1][9]. Group 1: Company Overview - Rocket Pharmaceuticals is a biotechnology company focused on developing gene therapies for rare diseases, specifically targeting Danon disease [4]. - The company had previously communicated strong progress in its gene therapy development, citing positive Phase 1 results as evidence of safety and efficacy [7]. Group 2: Legal Proceedings - A securities class action lawsuit has been filed against Rocket Pharmaceuticals, alleging that the company misled investors regarding the safety and progress of the RP-A501 trial [2][4]. - The lawsuit covers shareholders who purchased Rocket stock between February 27, 2025, and May 26, 2025, focusing on whether the company provided materially false and misleading statements about the trial [5]. Group 3: Allegations and Misconduct - Plaintiffs claim that Rocket Pharmaceuticals failed to disclose significant protocol changes and known risks associated with serious adverse events, including patient deaths, despite publicly expressing confidence in the trial's progress [6][8]. - The class action complaint alleges that the company amended the study protocol to introduce a new immunomodulatory agent without informing investors, which contributed to the inflated stock price prior to the FDA's announcement [8][10].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between September 17, 2024, and May 26, 2025 [1]. - Defendants allegedly made positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) [2]. - Following the announcement of a clinical hold by the FDA due to a SAE, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until August 11, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4].

Core Viewpoint - Berger Montague PC is investigating Rocket Pharmaceuticals for potential violations of federal securities laws related to the RP-A501 trial, which allegedly concealed safety concerns leading to significant investor losses [1][2]. Company Overview - Rocket Pharmaceuticals is based in Cranbury, New Jersey, focusing on research and clinical programs in genetic medicine [2]. - The company introduced a new immunomodulatory agent into the RP-A501 protocol without disclosing this information to shareholders, which preceded a fatal adverse event [2]. Stock Performance - Following the announcement of an FDA clinical hold, Rocket Pharmaceuticals' stock price declined nearly 37% over two trading days [2]. Legal Proceedings - A class action has been filed for individuals who purchased Rocket Pharmaceuticals securities from September 17, 2024, to May 26, 2025, with a deadline to file for lead plaintiff set for August 11, 2025 [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 11, 2025 [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities between September 17, 2024, and May 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 11, 2025 [3]. - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, defendants made false and misleading statements regarding the effectiveness and safety of RP-A501, which was overstated [5]. - Specific claims include that RP-A501 was less effective than represented, and that changes to its clinical trial protocol increased the risk of Serious Adverse Events [5].

WHAT'S NEXT? If you suffered a loss in Rocket during the relevant time frame, you have until August 11, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has ...

Core Viewpoint - Rocket Pharmaceuticals is facing a class action lawsuit for allegedly concealing safety concerns related to its RP-A501 trial, which has resulted in significant investor losses [1][2]. Company Overview - Rocket Pharmaceuticals is based in Cranbury, New Jersey, and focuses on research and clinical programs in genetic medicine [2]. Legal Issues - The lawsuit claims that Rocket Pharmaceuticals failed to disclose the introduction of a new immunomodulatory agent in the RP-A501 protocol before a patient experienced a fatal adverse event [2]. - Following the announcement of an FDA clinical hold, Rocket Pharmaceuticals' stock price declined nearly 37% over two trading days [2]. Class Action Details - Individuals who purchased Rocket Pharmaceuticals securities from September 17, 2024, to May 26, 2025, may be eligible to join the class action [3]. - The deadline to file for lead plaintiff status is August 11, 2025 [3].

SAN DIEGO, July 28, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit – captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049, and pending in the District of New Jersey – seeks to represent purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities and charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals' executives with violations of the Securities Exchange Act of 1934. A subsequently filed ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 28, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals" or the "Company") (NASDAQ: RCKT) investors of a class action representing investors that bought securities between February 27, 2025 and May 26, 2025, inclusive (the "Class Period"). Rocket Pharmaceuticals investors have until August 11, 2025 to file a lead plaintiff motion. Investors are e ...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/rocket-pharmaceuti ...

ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals” or the “Company”) (NASDAQ: RCKT). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to adequately disclose that Rocket Pharmaceuticals knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. If you purchased shares of Rocket Pharmaceuticals between February 27, 202 ...